Business News • PR NewsWire • Sanofi's Investigational Semuloparin in Cancer Patients Initiating Chemotherapy Shows a 64% Risk Reduction in Life-Threatening Venous Thrombo-Embolism

Sanofi's Investigational Semuloparin in Cancer Patients Initiating Chemotherapy Shows a 64% Risk Reduction in Life-Threatening Venous Thrombo-Embolism

Sanofi's Investigational Semuloparin in Cancer Patients Initiating Chemotherapy Shows a 64% Risk Reduction in Life-Threatening Venous Thrombo-Embolism

BRIDGEWATER, N.J., June 4, 2011 /PRNewswire/ -- Sanofi US (EURONEXT: SAN and NYSE: SNY) announced today results of the pivotal SAVE-ONCO study which demonstrated that, in cancer patients initiating a chemotherapy regimen, investigational semuloparin significantly reduced the risk of the composite of

View More : http://www.prnewswire.com/news-releases/sanofis-investigational-semuloparin-in-cancer-patients-initiating-chemotherapy-s...

Releted News by prnewswire

"Historic Victory for Workers" as Connecticut Legislature Completes Work on Paid Sick Days Bill; Governor Poised to Make Connecticut First State to Guarantee Workers the Right to Earn Paid Sick Days

Learning ZoneXpress Unveils USDA MyPlate Products to Use in the Classroom

Sanofi's Investigational Semuloparin in Cancer Patients Initiating Chemotherapy Shows a 64 % Risk Reduction in Life-Threatening Venous Thrombo-Embolism

Study Finds Treatment with Metreleptin Improved Diabetes and Lipid Control in Patients with Partial Lipodystrophy

Full Speed Ahead! The National WWII Museum Unveils New $3.2 Million Restoration Pavilion